Dupont Jakob
Director at PYXS; EVP, Head of R&D at ATRA; Chief Medical Officer at GOSS, and 1 more
- Sold, on record
- $2.2M
- Dollars the filings state
- Form 4 sales
- 29
- Latest Jun 30, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 4
- Filed as an executive or holder
Companies
- PYXSPyxis Oncology, Inc.Director
- ATRAAtara Biotherapeutics, Inc.EVP, Head of R&D
- GOSSGossamer Bio, Inc.Chief Medical Officer
- OncoMed Pharmaceuticals IncSVP & Chief Medical Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- ATRA49,169 shares
- GOSS41,994 shares
- OncoMed Pharmaceuticals Inc38,662 shares
- PYXS35,000 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale ATRAPlan not statedJan 3 2022
Sold 5,000 shares at $16.01 ($80k)
Dupont Jakob, EVP, Head of R&D
Sold 5.2% of holdings ($1.5M position)90,594 shares left1x usual sizeFiling
- 2 Form 4 sale ATRAPlan not statedFeb 10 +38 days
Sold 5,000 shares at $16.00 ($80k)
Dupont Jakob, EVP, Head of R&D
Sold 5.2% of holdings ($1.5M position)90,594 shares left1x usual sizeFiling
- 3 Form 4 sale ATRAPlan not statedMar 1 +19 days
Sold 2,221 shares at $9.86 ($22k)
Dupont Jakob, EVP, Head of R&D
Sold 1.3% of holdings ($1.7M position)166,879 shares left0.4x usual sizeFiling
- 4 Form 4 sale ATRAPlan not statedMay 17 +77 days
Sold 3,873 shares at $5.32 ($21k)
Dupont Jakob, EVP, Head of R&D
Sold 2.3% of holdings ($888k position)163,006 shares left0.8x usual sizeFiling
- 5 Form 4 sale ATRAPlan not statedAug 16 +91 days
Sold 4,124 shares at $5.03 ($21k)
Dupont Jakob, EVP, Head of R&D
Sold 2.5% of holdings ($820k position)158,882 shares left0.8x usual sizeFiling
- 6 Form 4 sale ATRAPlan not statedNov 16 +92 days
Sold 4,342 shares at $4.49 ($19k)
Dupont Jakob, EVP, Head of R&D
Sold 2.7% of holdings ($713k position)154,540 shares left1x usual sizeFiling
- 7 Form 4 sale ATRAPlan not statedMar 2 +106 days
Sold 5,074 shares at $3.63 ($18k)
Dupont Jakob, EVP, Head of R&D
Sold 1.7% of holdings ($1.1M position)290,794 shares left1.2x usual sizeFiling
- 8 Form 4 sale PYXSRoutineJun 30 +1216 days
Sold 35,000 shares at $3.06 ($107k)
Dupont Jakob, Director
10b5-1 planSold 47.5% of holdings ($226k position)38,741 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales and notices (29)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | PYXS | Director | Form 4 sale | 35,000 | $107k | 47.5% | Routine | SEC |
| Mar 2, 2023 | ATRA | EVP, Head of R&D | Form 4 sale | 5,074 | $18k | 1.7% | Plan not stated | SEC |
| Nov 16, 2022 | ATRA | EVP, Head of R&D | Form 4 sale | 4,342 | $19k | 2.7% | Plan not stated | SEC |
| Aug 16, 2022 | ATRA | EVP, Head of R&D | Form 4 sale | 4,124 | $21k | 2.5% | Plan not stated | SEC |
| May 17, 2022 | ATRA | EVP, Head of R&D | Form 4 sale | 3,873 | $21k | 2.3% | Plan not stated | SEC |
| Mar 1, 2022 | ATRA | EVP, Head of R&D | Form 4 sale | 2,221 | $22k | 1.3% | Plan not stated | SEC |
| Feb 10, 2022 | ATRA | EVP, Head of R&D | Form 4 sale | 5,000 | $80k | 5.2% | Plan not stated | SEC |
| Jan 3, 2022 | ATRA | EVP, Head of R&D | Form 4 sale | 5,000 | $80k | 5.2% | Plan not stated | SEC |
| Dec 1, 2021 | ATRA | EVP, Head of R&D | Form 4 sale | 5,000 | $90k | 5.2% | Plan not stated | SEC |
| Nov 16, 2021 | ATRA | EVP, Head of R&D | Form 4 sale | 2,199 | $38k | 2.4% | Plan not stated | SEC |
| Nov 2, 2021 | ATRA | EVP, Head of R&D | Form 4 sale | 5,000 | $82k | 5.1% | Plan not stated | SEC |
| Aug 17, 2021 | ATRA | EVP, Head of R&D | Form 4 sale | 2,152 | $27k | 2.3% | Plan not stated | SEC |
| May 18, 2021 | ATRA | EVP, Head of R&D | Form 4 sale | 5,184 | $75k | 5.2% | Plan not stated | SEC |
| Dec 30, 2019 | GOSS | Chief Medical Officer | Form 4 sale | 41,994 | $632k | 100.0% | Unusual | SEC |
| Jan 11, 2016 | OncoMed Pharmaceuticals Inc | SVP & Chief Medical Officer | Form 4 sale | 2,500 | $50k | 10.8% | Plan not stated | SEC |
| Jan 7, 2016 | OncoMed Pharmaceuticals Inc | SVP & Chief Medical Officer | Form 4 sale | 2,162 | $48k | 9.5% | Plan not stated | SEC |
| Dec 10, 2015 | OncoMed Pharmaceuticals Inc | SVP & Chief Medical Officer | Form 4 sale | 2,500 | $51k | 9.9% | Plan not stated | SEC |
| Nov 10, 2015 | OncoMed Pharmaceuticals Inc | SVP & Chief Medical Officer | Form 4 sale | 2,500 | $53k | 9.9% | Plan not stated | SEC |
| Oct 26, 2015 | OncoMed Pharmaceuticals Inc | SVP & Chief Medical Officer | Form 4 sale | 5,000 | $100k | 18.0% | Unusual | SEC |
| Aug 10, 2015 | OncoMed Pharmaceuticals Inc | SVP & Chief Medical Officer | Form 4 sale | 2,500 | $56k | 10.0% | Plan not stated | SEC |
| Jul 10, 2015 | OncoMed Pharmaceuticals Inc | SVP & Chief Medical Officer | Form 4 sale | 2,500 | $50k | 10.0% | Plan not stated | SEC |
| Jul 6, 2015 | OncoMed Pharmaceuticals Inc | SVP & Chief Medical Officer | Form 4 sale | 2,500 | $53k | 10.0% | Plan not stated | SEC |
| Apr 10, 2015 | OncoMed Pharmaceuticals Inc | SVP & Chief Medical Officer | Form 4 sale | 1,500 | $40k | 6.3% | Plan not stated | SEC |
| Mar 10, 2015 | OncoMed Pharmaceuticals Inc | SVP & Chief Medical Officer | Form 4 sale | 1,500 | $41k | 6.5% | Plan not stated | SEC |
| Feb 10, 2015 | OncoMed Pharmaceuticals Inc | SVP & Chief Medical Officer | Form 4 sale | 1,500 | $36k | 6.5% | Plan not stated | SEC |
| Jan 12, 2015 | OncoMed Pharmaceuticals Inc | SVP & Chief Medical Officer | Form 4 sale | 1,500 | $39k | 6.5% | Plan not stated | SEC |
| Jan 5, 2015 | OncoMed Pharmaceuticals Inc | SVP & Chief Medical Officer | Form 4 sale | 7,500 | $173k | 25.8% | Unusual | SEC |
| Jul 23, 2014 | OncoMed Pharmaceuticals Inc | SVP & Chief Medical Officer | Form 4 sale | 1,500 | $35k | 6.7% | Plan not stated | SEC |
| Jun 26, 2014 | OncoMed Pharmaceuticals Inc | SVP & Chief Medical Officer | Form 4 sale | 1,500 | $35k | 6.7% | Plan not stated | SEC |